tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Rapt Therapeutics price target lowered to $38 from $51 at Wells Fargo

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Rapt Therapeutics (RAPT) to $38 from $51 and keeps an Overweight rating on the shares. The firm sees potential for value inflection in RAPT shares in the second half of 2025 upon partner Jemincare’s China study readouts in lateral indications if RPT904 could show better PD and/or efficacy than Xolair in related indications.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1